# Appendix C: Advanced Imaging and Photodynamic Therapy in Cancer Research

## Introduction: Visualizing and Treating Cancer

This appendix covers specialized imaging techniques and photodynamic therapy (PDT) methods that are essential for contemporary cancer research. These approaches enable researchers to visualize tumors in living animals, track molecular events in real-time, and selectively destroy cancer cells using light-activated therapeutics.

**Core Techniques Covered:**
- Advanced flow cytometry and FACS
- Fluorescence microscopy for cancer imaging
- In vivo optical imaging systems
- Photodynamic therapy protocols
- Orthotopic tumor models for PDT research

---

## Part 1: Advanced Flow Cytometry and FACS

### C.1 Principles of Flow Cytometry

**C.1.1 How Flow Cytometry Works**

Flow cytometry enables rapid analysis of thousands of cells per second. "After a liquid sample with stained cells is injected into a flow cytometer, the cells are forced to form a single file stream through hydrodynamic focusing. The cells in a single file stream are illuminated as they travel through a laser beam, and the optical and fluorescence signals of each cell are generated and detected."¹

**Key Components:**
1. **Fluidics**: Hydrodynamic focusing creates single-file cell stream
2. **Optics**: Laser excitation and light collection
3. **Electronics**: Convert light signals to digital data
4. **Software**: Data analysis and visualization

**Light Scatter Properties:**

"The laser beam is scattered by the cells and their contents, and the light scattered along the axis of the projected laser is called forward scatter, which depends on the size and surface area of the cell. The light scattered at approximately 90°, which depends on the cell granularity, nucleus, and internal complexity of the cell, is called side scatter."²

**Applications:**
- FSC (Forward Scatter) = Cell size
- SSC (Side Scatter) = Cell granularity/complexity
- Together allow separation of cell populations

---

### C.2 Antibody-Based Detection

**C.2.1 Surface Marker Analysis**

Flow cytometry excels at detecting cell surface proteins like receptors. "Fluorochrome-labeled primary antibodies are used to target specific cell antigens. The fluorochromes are excited by the laser, and the emitted light of a longer wavelength is allowed to pass through the lens, mirrors, and filters, thus separating and directing lights of different wavelengths to appropriate detectors."²

**Example: EGFR Expression Analysis**

To measure EGFR (Epidermal Growth Factor Receptor) expression:

1. **Prepare cells**: Single-cell suspension
2. **Block non-specific binding**: Fc receptor blocking
3. **Stain with anti-EGFR antibody**: Fluorophore-conjugated (e.g., FITC, PE, APC)
4. **Include controls**:
   - Unstained cells
   - Isotype control (same antibody type, irrelevant specificity)
   - Fluorescence Minus One (FMO) control
5. **Acquire data**: Collect ≥10,000 events
6. **Analyze**: Gate on live single cells, then measure EGFR intensity

**Key Measurement:**
"The intensity of the fluorescent signal is proportional to the expression level of the antigen, to which the corresponding fluorescently labeled antibody binds."¹

---

**C.2.2 Immunoconjugate Binding Assays**

For targeted therapy research (e.g., antibody-drug conjugates, nanobody-photosensitizer conjugates):

**Protocol:**
1. Prepare cancer cells expressing target antigen
2. Incubate with fluorescent immunoconjugate (concentration series)
3. Wash unbound conjugate
4. Analyze by flow cytometry
5. Measure binding (% positive cells, mean fluorescence intensity)
6. Calculate binding affinity (Kd) if desired

**Critical Controls:**
- Cells without target antigen (negative control)
- Free antibody competition (specificity control)
- Unconjugated antibody (conjugation effect control)

---

**C.2.3 Sample Preparation for Flow Cytometry**

**From NCBI Bookshelf guidance:**

"Sample preparation for FCM analysis varies according to the specimen types and the antigens to be analyzed. The cell suspension generated by mincing tissue should be filtered to remove large particles that may clog the cytometer tubing and/or bind antibodies non-specifically."¹

**Standard Protocol:**
1. Obtain single-cell suspension
2. Count cells and adjust concentration (typically 1×10⁶ cells/ml)
3. "For optimal results, it is recommended to process a fresh sample, preferably within 18 hours"²
4. Use "stain-lyse-wash protocol"²:
   - Incubate with fluorescent antibodies
   - Lyse red blood cells if needed
   - Wash and centrifuge
5. Resuspend in appropriate buffer
6. Filter before running (35-40 μm mesh)

**Quality Control:**

"Quality control (QC) is a critical aspect of laboratory operations, especially in flow cytometry... QC involves several key assessments to maintain assay integrity and reliability, including regular checks and calibrations of flow cytometry instruments, such as lasers, detectors, and fluidics systems."²

---

### C.3 Fluorescence-Activated Cell Sorting (FACS)

**C.3.1 FACS Principles**

FACS physically separates cells based on fluorescence properties. "Modern flow cytometry instruments can sort through thousands of cells per second."³

**Applications in Cancer Research:**
- Isolate cancer stem cell populations
- Purify cells expressing specific markers
- Separate transfected from untransfected cells
- Collect rare circulating tumor cells

**Example: Sorting GFP-Positive Cells**

"U87-NES-TGL cells or U87-Δ45-TGL cells were sorted for positive GFP expression using FACS with 488-nm excitation beam and 510-nm emission filter."⁴

---

## Part 2: Fluorescence Microscopy Techniques

### C.4 Basic Fluorescence Microscopy

**C.4.1 Principles of Fluorescence**

"In fluorescence microscopy, the specimen is illuminated with a wavelength of light that falls within the linear absorption spectrum of the molecule. A single photon is absorbed by the molecule and promotes it to an excited electronic state. Upon thermal equilibration and relaxation back to its ground state, the molecule will emit a photon that is shifted toward longer wavelengths."⁵

**Standard Fluorophores:**
- **DAPI**: Blue (DNA staining)
- **FITC/GFP**: Green (proteins, antibodies)
- **Rhodamine/Texas Red**: Red (proteins, antibodies)
- **Cy5**: Far-red (low autofluorescence background)

---

**C.4.2 Green Fluorescent Protein (GFP)**

GFP revolutionized cell biology. "Virtually any protein of interest can be genetically engineered as a GFP-fusion protein, and then imaged in living cells by fluorescence microscopy."⁶

**Advantages:**
- Genetically encoded (no staining needed)
- Live-cell imaging compatible
- Stable expression possible
- Multiple color variants available (CFP, YFP, RFP, mCherry)

**Applications:**
- Track protein localization
- Monitor gene expression
- Label specific cell populations
- Reporter gene assays

**Engineering Variants:**

"Understanding the physics and chemistry of photon absorption and fluorescent re-emission enabled the engineering of GFP mutants in a rainbow of colors and with exceptional photophysical properties."⁷

---

### C.5 Advanced Microscopy Techniques

**C.5.1 Confocal Microscopy**

Confocal microscopy provides optical sectioning by eliminating out-of-focus light.

**Principle:**
"A pinpoint of light is focused on the specimen at a particular depth, and emitted fluorescent light is collected by a detector. Before reaching the detector, the fluorescent light emitted by the specimen must pass through a confocal aperture placed at precisely the point where light emitted from the chosen depth comes to a focus."⁸

**Advantages:**
- Optical sectioning without physical sectioning
- 3D image reconstruction possible
- Reduced background fluorescence
- Better resolution than widefield

**Applications in Cancer Research:**
- Tumor spheroid imaging
- Tissue architecture analysis
- Subcellular protein localization
- Co-localization studies

---

**C.5.2 Two-Photon Microscopy**

**Principle:**
"Two-photon excitation microscopy... requires the simultaneous absorption of two photons" to excite fluorophores.⁵

**Key Advantages:**
- **Deeper tissue penetration**: Near-infrared excitation scatters less
- **Reduced photobleaching**: Only focal plane is excited
- **Less phototoxicity**: Better for live imaging
- **Intrinsic optical sectioning**: No pinhole needed

**Applications:**
- Intravital imaging (imaging in living animals)
- Deep tissue imaging (hundreds of microns)
- Long-term live-cell imaging
- "Live-cell imaging 'at the extreme'... we opened the skull of an anaesthetized mouse and looked into the brain"⁹

---

**C.5.3 Super-Resolution Microscopy**

Techniques that break the diffraction limit (~200 nm):

**STED (Stimulated Emission Depletion):**
- Resolution: 20-40 nm standard
- Can achieve ~2 nm with optimal fluorophores⁹
- Live-cell compatible

**STORM/PALM:**
- Single-molecule localization
- Resolution ~20 nm
- Requires specialized fluorophores

**Applications:**
- Visualize molecular complexes
- Protein clustering analysis
- Membrane organization
- Nanoscale tumor biology

---

### C.6 Activatable Fluorescent Probes

**C.6.1 Principles of Activatable Fluorophores**

These probes only fluoresce upon activation (enzyme cleavage, pH change, binding event).

**Advantages:**
- Low background signal (quenched when inactive)
- High signal-to-noise ratio
- Reports on biological activity, not just presence
- Can detect enzyme activity in vivo

**Types:**
1. **Enzyme-activatable**: Protease cleavage releases quenching
2. **pH-sensitive**: Tumor microenvironment activation
3. **ROS-sensitive**: Activated by reactive oxygen species
4. **Target-binding**: Fluorescence upon receptor binding

**Cancer-Specific Applications:**
- Detecting tumor margins during surgery
- Monitoring protease activity (MMPs, cathepsins)
- Identifying aggressive vs. indolent tumors
- Real-time surgical guidance

---

## Part 3: In Vivo Optical Imaging

### C.7 Bioluminescence Imaging (BLI)

**C.7.1 Principles and Applications**

"Reporter gene-bioluminescence imaging (BLI) is based on light emission and detection by specific cooled charge coupled device (CCD) cameras."¹⁰

**Key Advantage:**
"The significant advantage of this approach is that the background levels are very low compared with fluorescence, and no exciting light is needed."¹¹

**Standard System: Luciferase-Luciferin**

"In the vast majority of bioluminescence imaging studies, the bioluminescent probe is a modified luciferase enzyme that catalyzes a light-producing oxidation when chemical substrates (luciferin) are naturally present or supplied."¹¹

---

**C.7.2 BLI Protocol for Tumor Imaging**

Based on standardized IVIS imaging procedures:¹²

**Equipment Setup:**
1. "Place a black XFM-1 low fluorescence mat inside the imaging chamber with the matt side facing upward"¹²
2. "Start the anesthesia/isoflurane system—this should be connected to the IVIS and to an induction chamber"¹²
3. Check oxygen supply and isoflurane levels
4. Turn on waste gas scavenger

**Animal Preparation:**
1. "Transfer 3–5 mice to the induction chamber and close it tightly"¹²
2. "Initiate anesthesia using 1.5 L per minute O2 with 4% isoflurane"¹²
3. Wait for full anesthesia (respiratory rate slows)

**Imaging Procedure:**
1. "Inject 150 mg/kg beetle luciferin subcutaneously"¹² (or IP)
2. "Record the time of luciferin injection"¹²
3. Wait 10-15 minutes for substrate distribution
4. Transfer anesthetized mice to imaging chamber (maintain anesthesia via nose cones)
5. Image sequence (typically every 1-2 minutes for 10-20 minutes)
6. Select peak signal image for analysis

**Route Considerations:**

"It is preferable to inject luciferin subcutaneously or intraperitoneally. While subcutaneous injection results in a slightly lower signal compared with intraperitoneal injection it has a longer and flatter signal kinetics making it more suitable for taking multiple images."¹²

---

**C.7.3 Data Analysis**

**Quantification:**
- Define Regions of Interest (ROIs)
- Measure total photon flux (photons/second)
- Background subtraction
- Normalize to baseline or control animals

**Longitudinal Monitoring:**

"BLI is commonly used for the tracking of stem cells delivered to organs within small living animals... The BLI signal is only emitted when cells are viable, and thus can be used for the longitudinal monitoring of stem cell survival."¹⁰

**Advantages:**
- Non-invasive monitoring of same animals over time
- Reduces animal numbers needed
- Detects deep tissue/metastatic tumors
- Quantitative measurement of tumor burden

**Limitations:**
- Requires genetic modification (luciferase expression)
- Signal attenuation by tissue depth
- Cannot provide anatomical detail
- Substrate injection required

---

### C.8 Fluorescence Imaging in Vivo

**C.8.1 Fluorescence vs. Bioluminescence**

"Use of GFP constitutes one of the first examples of the application of reporter genes for in vivo imaging of trans-gene expression. Fluorescence reporter proteins are very sensitive and result in the emission of a strong signal. However, both light excitation and emission undergo significant tissue attenuation (due to absorption) and tissue refraction, which limits the tissues that can be studied (up to 2 mm in depth)."¹⁰

**When to Use Fluorescence:**
- Superficial tumors
- Ex vivo imaging of excised tissues
- High-resolution applications
- Multiple simultaneous markers

**When to Use Bioluminescence:**
- Deep tissue imaging
- Longitudinal studies
- Low background critical
- Single marker sufficient

---

**C.8.2 Near-Infrared Fluorescence Imaging**

**Advantages of NIR (650-900 nm):**
- Deeper tissue penetration
- Lower autofluorescence
- Reduced scattering
- Better for in vivo imaging

**NIR Fluorophores:**
- Cy5, Cy5.5, Cy7
- IRDye 800CW
- ICG (Indocyanine Green) - FDA approved
- Alexa Fluor 680, 750

**Applications:**
- Intraoperative tumor margin detection
- Lymph node mapping
- Vascular imaging
- Targeted imaging with antibody conjugates

---

### C.9 Multi-Modal Imaging

**C.9.1 Combining Imaging Modalities**

Modern research often uses multiple reporters simultaneously. For example, "a triple fusion reporter gene that has a fluorescent reporter gene, a bioluminescent reporter gene, and a PET reporter gene" allows comprehensive imaging.¹⁰

**Example System: HSV1-TK/GFP/Fluc**

This triple reporter enables:⁴
- **GFP**: Fluorescence microscopy, FACS sorting
- **Firefly luciferase**: Bioluminescence imaging
- **HSV1-TK**: PET/SPECT imaging with radiolabeled substrates

**Applications:**
- Validate bioluminescence with fluorescence
- Combine anatomical (MRI/CT) with functional (optical) imaging
- Confirm ex vivo what was seen in vivo

---

## Part 4: Photodynamic Therapy (PDT)

### C.10 PDT Principles and Mechanism

**C.10.1 Basic Mechanism**

"Photodynamic therapy basically requires three things i.e. a photosensitizer, a light source, and oxygen."¹³

**How PDT Works:**

When a photosensitizer is exposed to light of appropriate wavelength in the presence of oxygen:
1. Light activates photosensitizer
2. Energy transfer to molecular oxygen
3. Generation of reactive oxygen species (ROS), primarily singlet oxygen
4. ROS damage cellular components
5. Cell death through apoptosis and/or necrosis

"These intermediates act on essential cellular components leading to apoptosis and necrosis due to irreversible oxidization."¹³

---

**C.10.2 Photosensitizers**

**Major Classes:**

**Porphyrin-Based:**
- **Photofrin**: First-generation, FDA-approved
- **mTHPC (Foscan)**: Second-generation, more selective
- **ALA/MAL**: Prodrugs converted to PpIX in cells

**Clinical Photosensitizers for Oral/Head-Neck Cancer:**

From clinical studies, common agents include:
- **5-ALA (aminolevulinic acid)**: "20% aminolevulinic acid was more effective than other photosensitizers"¹⁴
- **Methyl aminolevulinate (MAL)**: Similar to ALA
- **Photofrin**: Multiple cancer types
- **mTHPC**: Advanced lesions

**Selectivity:**

"This selectivity arises from the accumulation of porphyrin metabolites, which are produced when topical preparations, such as 5-ALA and MAL, are incubated topically on the skin before exposure to blue or red light."¹⁵

---

**C.10.3 ALA-Based PDT**

**Special Characteristics:**

"The drug-light dependence of some photosensitizers is especially complex, such as with ALA-PpIX where the photosensitizer is produced within the cells after injection of ALA. The maximal production of PpIX is observed at 4 to 6 h after injection."¹⁶

**Fractionation Advantage:**

"Recent observations have shown that a pretreatment of light followed by a dark interval of 2 h to allow regeneration of PpIX significantly increases the PDT effect, as measured in normal mouse skin."¹⁶

---

### C.11 Light Dosimetry

**C.11.1 Critical Parameters**

"In principle, photodynamic response is obtained wherever a photosensitizer, oxygen, and light occur simultaneously."¹⁶

**Key Dosimetric Factors:**

1. **Drug Dose**: Photosensitizer concentration
2. **Light Dose**: Energy delivered (J/cm²)
3. **Fluence Rate**: Power density (mW/cm²)
4. **Wavelength**: Must match photosensitizer absorption
5. **Oxygen**: Critical cofactor

---

**C.11.2 Drug-Light Reciprocity**

"Early studies indicated that the presence of photosensitizer and light were of equal importance, and that there existed some level of drug-light reciprocity in the tissue response, in that decreasing the drug level by some factor would cause the same loss of effect, equivalent to alternatively decreasing the light delivered by the same factor."¹⁶

**Important Caveat:**

"This reciprocity is lost in the presence of additional mitigating factors such as photobleaching, oxygen limitation, and excessive photosensitizer concentration leading to self-shielding of the light delivered."¹⁶

---

**C.11.3 Light Delivery Techniques**

**Surface Illumination:**
- Direct light application
- Fiber optic probes
- LED arrays
- Laser sources

**Interstitial Illumination:**
- Cylindrical diffusing fibers
- Multiple fiber placement for large tumors
- Real-time dosimetry monitoring

**Critical Challenge:**

"Many clinical PDT studies have ended without success because of problems with delivering the appropriate amount of light to the tissue, or from over delivery of light causing perforations or strictures."¹⁶

---

**C.11.4 Threshold Effects**

"There appears to be a threshold component for PDT effects to be lethal, below which tissue damage is reparable."¹⁶

**Practical Implications:**
- Must achieve minimum effective dose
- Too little = treatment failure
- Too much = excessive normal tissue damage
- Dosimetry critical for reproducibility

---

### C.12 PDT Protocols for Cancer Research

**C.12.1 In Vitro PDT Cytotoxicity**

**Basic Protocol:**
1. Seed cells in multi-well plates (96-well common)
2. Add photosensitizer (concentration series)
3. Incubate (timing depends on photosensitizer):
   - ALA: 4-6 hours for optimal PpIX accumulation
   - Other agents: typically 2-24 hours
4. Wash cells to remove extracellular photosensitizer
5. Irradiate with appropriate wavelength light
   - Measure fluence with calibrated detector
   - Record total energy delivered (J/cm²)
6. Post-PDT incubation (typically 24h)
7. Assess cell viability/death

**Light Sources:**
- LED arrays (narrow spectrum, cost-effective)
- Filtered lamps (broad spectrum)
- Lasers (precise wavelength, expensive)

---

**C.12.2 Measuring PDT-Induced Cell Death**

**Recommended Assays:**

1. **Immediate viability** (4-6h post-PDT):
   - Annexin V/PI: Distinguish apoptosis vs necrosis
   - Trypan blue: Quick assessment

2. **Long-term survival** (24-72h):
   - MTT/ATP assays: Metabolic activity
   - Clonogenic survival: Gold standard for PDT
   - LDH release: Membrane damage

3. **Mechanism studies**:
   - Caspase activation: Apoptotic pathway
   - ROS detection: Confirm singlet oxygen generation
   - Mitochondrial membrane potential: ΔΨm loss

**Clonogenic Assay Post-PDT:**
- Most clinically relevant endpoint
- Plate cells immediately after PDT (low density)
- Allow 7-14 days colony formation
- Fix, stain, count colonies
- Calculate surviving fraction

---

## Part 5: Orthotopic Tumor Models for PDT

### C.13 Orthotopic Oral Cancer Models

**C.13.1 Rationale for Orthotopic Models**

"In vitro studies are certainly very valuable to evaluate the therapeutic potential of PDT approaches, but many aspects such as bio-distribution of the photosensitizers, penetration through tissues, and clearance are not taken into account. In vivo studies are therefore essential to assess the influence of such factors."¹⁷

**Why Orthotopic?**
- Anatomically relevant site
- Proper microenvironment
- Appropriate vasculature
- Clinically translatable
- Allows assessment of light penetration

---

**C.13.2 Establishing Orthotopic Oral Cancer Models**

**Common Model Systems:**

Based on published research:¹⁸
1. **Murine cheek pouch model**: Hamster or mouse
2. **Tongue implantation**: SCC cells injected into tongue
3. **Buccal mucosa model**: Cells implanted in cheek
4. **Floor of mouth model**

**Example Protocol Elements:**

**Subcutaneous Model (for comparison):**
- Cell line: Cal-33, SCC-9, HSC-3, etc.
- Cell number: 1-5 × 10⁶ cells
- Vehicle: PBS or Matrigel
- Injection site: Flank (subcutaneous)
- Monitor: Caliper measurements

**Orthotopic Tongue Model:**
- Anesthetize mouse
- Expose tongue
- Inject cells (typically 0.5-1 × 10⁶ cells in 20-50 μL)
- Cell suspension may include Matrigel (1:1)
- Close surgical site
- Monitor tumor growth by palpation or imaging

**VX-2 Rabbit Model:**

"An anatomically relevant orthotopic VX-2 rabbit model" is used for oral cancer PDT research.¹⁹ This model:
- Uses New Zealand White rabbits
- VX-2 carcinoma implanted in buccal mucosa
- Larger animal allows better surgical access
- More clinically relevant size for light delivery

---

### C.14 PDT Treatment in Orthotopic Models

**C.14.1 Photosensitizer Administration**

**Routes:**
- **Intravenous**: Systemic delivery
- **Topical**: Surface lesions (oral cavity accessible)
- **Intratumoral**: Direct injection

**Timing:**

Photosensitizer must accumulate in tumor before light treatment:
- **Photofrin**: 24-48 hours
- **mTHPC**: 24-96 hours  
- **ALA**: 4-6 hours (shorter due to metabolic conversion)
- **Verteporfin**: 15 minutes (ophthalmology)

**Example from Research:**

"Tumors selectively uptake PS [porphysome nanoparticles] (10 mg/kg, i.v.) with 6- to 40-fold greater concentration versus muscle 24 hours post-injection."¹⁹

---

**C.14.2 Light Delivery to Orthotopic Oral Tumors**

**Challenges:**
- Complex anatomy
- Need for intraoral access
- Ensuring uniform light distribution
- Avoiding damage to normal tissue

**Delivery Systems:**
- Fiber optic probes
- Microlens diffusing tips
- LED panels for accessible lesions
- Multiple fiber placement for large tumors

**Light Parameters:**

Based on clinical and preclinical protocols:
- **Wavelength**: 630-690 nm (most photosensitizers)
- **Fluence**: 50-200 J/cm² (agent-specific)
- **Fluence rate**: 50-150 mW/cm² (affects oxygen depletion)
- **Treatment time**: Calculate from fluence/fluence rate

**Example:**
- Target fluence: 100 J/cm²
- Fluence rate: 100 mW/cm² = 0.1 J/(cm²·s)
- Treatment time: 1000 seconds = ~17 minutes

---

**C.14.3 Monitoring Treatment Response**

**Immediate Assessment:**
- Fluorescence of photosensitizer (shows distribution)
- Photosensitizer photobleaching (indicates light delivery)
- Edema/erythema (acute tissue response)

**Short-term (24-72h):**
- Tumor volume measurement (calipers or imaging)
- Necrosis assessment (histology)
- Apoptosis markers (IHC: cleaved caspase-3, TUNEL)
- Vascular damage (perfusion studies)

**Long-term:**
- Tumor growth curves
- Complete response rate
- Survival analysis
- "Disease free survival at 5 years"²⁰ for clinical translation

---

### C.15 Photosensitizer Distribution Studies

**C.15.1 Ex Vivo Fluorescence**

Most photosensitizers are intrinsically fluorescent:
- Excise tumor and organs at various timepoints post-injection
- Image tissue fluorescence
- Quantify photosensitizer distribution

**C.15.2 In Vivo Fluorescence Imaging**

**Protocol:**
1. Administer fluorescent photosensitizer
2. Image at intervals (e.g., 1, 4, 24, 48h)
3. Measure tumor vs. normal tissue fluorescence
4. Calculate tumor-to-normal ratio
5. Optimize treatment timing

**Dual Use: Imaging and Therapy**

"Photosensitizers can also be used for fluorescence detection. If a tumor contains more of the photosensitizer than the surrounding normal tissue, its fluorescence can potentially be utilized to detect tumors."²¹

This is called **Photodynamic Detection (PDD)** or fluorescence-guided surgery.

---

## Part 6: Specialized Applications

### C.16 Photoimmunotherapy (PIT)

**C.16.1 Concept**

Combines antibody targeting with PDT:
- Antibody or nanobody targets cancer-specific antigen
- Conjugated to photosensitizer
- Selective tumor uptake
- Light activation causes targeted cell death

**Advantages:**
- Highly specific to cancer cells
- Spares normal tissue
- Can target residual disease
- Minimally invasive

**Example Application:**

"Nanobody-targeted PDT is one of such approaches, in which the variable domain of heavy-chain antibodies, i.e., nanobodies, are used to target photosensitizers selectively to cancer cells."¹⁷

EGFR-targeted nanobody-photosensitizer conjugates have shown efficacy in head and neck cancer models.

---

### C.17 Combination Imaging-Therapy Platforms

**C.17.1 Theranostic Nanoparticles**

**Example: Porphysome Nanoparticles**

"PORPHYSOME (PS) nanoparticles assembled from chlorin photosensitizer-containing building blocks (∼94,000 photosensitizers per particle) and capable of potent PDT"¹⁹

**Advantages:**
- High photosensitizer loading
- Enhanced optical properties
- Imaging agent and therapeutic in one
- Improved tumor uptake

**Multi-Modal Capabilities:**

Some systems combine:
- Fluorescence (optical imaging)
- MRI contrast (anatomical imaging)
- Therapeutic effect (PDT)

Example: "Bimodal lentiviral vector encoding myc-tagged human ferritin heavy chain and green fluorescent protein (GFP)" enables both MRI and optical imaging.²²

---

## Part 7: Practical Protocols

### C.18 Setting Up PDT Experiments

**C.18.1 In Vitro PDT Protocol Template**

**Day 1: Cell Seeding**
- Plate cells at 5,000-10,000 cells/well (96-well)
- Allow overnight attachment

**Day 2: Photosensitizer Incubation**
- Prepare photosensitizer dilutions in culture medium
- Include vehicle control (often DMSO)
- Incubate (typically 4-24h, agent-dependent)
- Keep plates in dark

**Day 3: Light Treatment**
- Remove photosensitizer medium
- Wash cells gently with PBS
- Add fresh medium
- Irradiate with calibrated light source
- Include controls:
  - Light only (no photosensitizer)
  - Drug only (no light)
  - Untreated control
- Return to incubator

**Day 4: Analysis**
- Assess cell viability (MTT, ATP, LDH)
- Measure apoptosis (Annexin V)
- Document morphology
- Analyze data

---

**C.18.2 In Vivo PDT Protocol for Orthotopic Oral Cancer**

**Tumor Establishment (Week 0):**
- Establish orthotopic tumors
- Allow 7-14 days for tumor take and growth
- Confirm tumor presence (palpation or imaging)

**PDT Treatment (Week 1-2):**

**Day of Treatment:**
1. Administer photosensitizer (IV or topical)
2. Wait for tumor accumulation (drug-specific interval)
3. Anesthetize animal
4. Position for light delivery
5. Deliver calibrated light dose
6. Monitor during treatment
7. Recover animal post-treatment

**Follow-up:**
- Daily monitoring for acute toxicity
- Tumor measurements 2-3× weekly
- Document response (caliper or imaging)
- Survival endpoints
- Histological analysis at study end

---

### C.19 Light Safety and Photosensitivity

**C.19.1 Protecting Patients/Animals**

**Systemic Photosensitization:**

"Photosensitivity reactions after the injection of verteporfin are quite common. Therefore patients are advised not to step out into the sunlight and completely cover the skin to avoid light exposure to the skin for 48 hours after injection."²³

**Precautions:**
- Dark housing for photosensitized animals
- Avoid bright procedural lights
- Red light for animal care (if needed)
- Time-dependent (varies by agent)

**Clinical Context:**

"Complications of PDT were mostly related to non-compliance to light restriction guidelines."²⁴

---

## Part 8: Troubleshooting and Optimization

### C.20 Common Issues in PDT Research

**Problem**: No cell killing despite light and drug
**Solutions:**
- Verify photosensitizer activity (measure fluorescence)
- Confirm light wavelength matches absorption peak
- Check oxygen levels (hypoxia inhibits PDT)
- Increase dose of light or drug
- Verify light source calibration

**Problem**: Excessive toxicity in dark controls
**Solutions:**
- Reduce photosensitizer concentration
- Shorten incubation time
- Improve washing to remove extracellular drug
- Some agents have inherent dark toxicity

**Problem**: Variable PDT response in vivo
**Solutions:**
- Standardize tumor size at treatment
- Ensure consistent light delivery (use fixed geometry)
- Account for tissue optical properties
- Monitor photosensitizer fluorescence before light

**Problem**: Poor tumor selectivity
**Solutions:**
- Optimize drug-light interval
- Consider targeted delivery (antibody conjugates, nanoparticles)
- Verify tumor uptake by fluorescence imaging
- Adjust dosing based on biodistribution

---

### C.21 Optimizing Light Dosimetry

**C.21.1 Fluence Rate Effects**

"Dose rate effects are thought to be inherently linked to oxygen dependency."¹⁶

**General Principle:**
- **High fluence rate**: Rapid treatment but oxygen depletion
- **Low fluence rate**: Allows oxygen replenishment, often more effective
- **Fractionation**: Multiple short treatments can be superior

**Example:**

"These preclinical studies appear to suggest that fluence rates lower than those being used currently should produce more efficient clinical PDT response."¹⁶

**Fractionation Timing:**

"Fractionation needs to be accomplished within seconds to minutes and, in contrast to ionizing radiation, is ineffective at longer intervals of hours, possibly because of efficient repair mechanisms following PDT. The key exception to this rule is ALA-PpIX photodynamic therapy in which fractionation on the time scale of hours has shown a significant advantage."¹⁶

---

## Part 9: Data Analysis and Reporting

### C.22 Quantifying PDT Response

**C.22.1 In Vitro Analysis**

**IC50 Determination:**
- Plot cell viability vs. light dose (or drug concentration)
- Calculate dose causing 50% cell death
- Report as J/cm² (light) or μM (drug concentration)

**Statistical Analysis:**
- Multiple independent experiments (n≥3)
- Technical replicates per condition
- ANOVA for multiple groups
- Post-hoc tests for pairwise comparisons

---

**C.22.2 In Vivo Tumor Response Criteria**

**Tumor Volume Changes:**

From clinical PDT studies: "Lesion size decreased by 1.38 cm² (95% CI: 0.39-2.36) after PDT"¹⁴

**Response Categories:**
- **Complete Response (CR)**: No detectable tumor
- **Partial Response (PR)**: ≥50% volume reduction
- **Stable Disease (SD)**: <50% reduction, <25% increase
- **Progressive Disease (PD)**: ≥25% volume increase

**Example from Research:**

"The overall complete response (CR) was 0.52 (95% CI: 0.36-0.68), while partial response (PR) reached 0.82 (95% CI: 0.74-0.88)"¹⁴

---

**C.22.3 Survival Analysis**

For preclinical studies with survival endpoints:

**Kaplan-Meier Curves:**
- Plot survival probability over time
- Compare treatment groups
- Log-rank test for significance

**Reporting:**
- Median survival time
- Survival at specific timepoints
- Hazard ratios
- "Local disease free survival at 5 years were 67 and 74 % for PDT and surgery groups"²⁰

---

## Part 10: Emerging Technologies

### C.23 Advanced Imaging Modalities

**C.23.1 Fluorescence Lifetime Imaging (FLIM)**

Measures fluorescence decay time rather than just intensity:
- Reports on molecular environment
- pH, oxygen, binding state affect lifetime
- Reduces artifacts from concentration variations
- "The decay time of the fluorescence is a characteristic parameter for fluorescent molecules and their environment"²⁵

---

**C.23.2 Intravital Microscopy**

Direct visualization of tumors in living animals:
- Surgical window preparation
- Chronic cranial windows for brain
- Abdominal window chambers
- Real-time observation of:
  - Cell migration
  - Vascular dynamics
  - Drug delivery
  - Treatment response

**Technical Challenges:**
- Requires surgical expertise
- Window clarity degrades over time
- Animal well-being considerations
- "Windows stay optically clear for 1–2 weeks, after which they show signs of bone regrowth"²⁶

---

### C.24 Clinical Translation Considerations

**C.24.1 Preclinical to Clinical PDT**

**Key Translation Steps:**
1. Demonstrate efficacy in relevant models
2. Establish optimal dosimetry
3. Define toxicity profile
4. Determine drug-light interval
5. Clinical trial design

**Advantages of PDT for Cancer:**

From clinical experience:¹⁵
- "Rather noninvasive procedure"
- "Minimal adverse effects and little downtime"
- "Treat multiple lesions simultaneously"
- "Minimal carcinogenic risk"
- "Superior cosmetic results"
- "Tissue sparing"

**Current Clinical Applications:**
- Skin cancers (basal cell, squamous cell)
- Oral premalignant lesions
- Early-stage oral cancer
- Barrett's esophagus with dysplasia
- Endobronchial tumors

---

## Part 11: Quality Control and Standardization

### C.25 Ensuring Reproducible Results

**C.25.1 Light Source Calibration**

**Essential Measurements:**
- Spectral output (wavelength verification)
- Power density (mW/cm²)
- Beam uniformity
- Stability over time

**Tools:**
- Calibrated spectroradiometer
- Power meter with appropriate detector
- Spatial mapping of beam profile

**Frequency:**
- Before each experiment (power)
- Monthly (full spectral analysis)
- After bulb/LED replacement

---

**C.25.2 Photosensitizer Quality Control**

**Verification:**
- Absorption spectrum (confirm identity)
- Fluorescence spectrum
- Concentration (Beer's law or fluorometry)
- Purity (HPLC if available)

**Storage:**
- Protect from light (dark vials/amber bottles)
- Refrigerate or freeze as appropriate
- Note reconstitution date
- Discard if degradation suspected (color change)

---

## Part 12: Quick Reference Guides

### C.26 Flow Cytometry Quick Start

**Basic Gating Strategy:**
1. FSC vs SSC: Identify cell population, exclude debris
2. FSC-A vs FSC-H: Exclude doublets (single cells)
3. Viability gate: Exclude dead cells (use live/dead dye)
4. Marker of interest: Analyze expression

**Antibody Staining Tips:**
- Use manufacturer-recommended concentration as starting point
- Titrate antibodies to find optimal dilution
- Stain on ice (30 min) for surface markers
- Permeabilize for intracellular markers
- Always include unstained and FMO controls

---

### C.27 PDT Quick Reference

**Selecting Light Dose:**

**Start with literature values for your photosensitizer:**
- Photofrin: ~100-200 J/cm²
- ALA-PpIX: ~50-150 J/cm²
- mTHPC: ~10-20 J/cm²
- Then optimize for your model

**Rule of Thumb:**
- In vitro requires less light than in vivo
- Monolayers more sensitive than 3D cultures
- Orthotopic tumors need more light than subcutaneous

---

### C.28 Imaging Troubleshooting

**High Background Fluorescence:**
- Use NIR fluorophores (less autofluorescence)
- Reduce excitation intensity
- Optimize exposure time
- Use appropriate filters
- Consider spectral unmixing

**Weak Signal:**
- Increase fluorophore concentration
- Longer exposure (if photobleaching not issue)
- Binning pixels (trades resolution for sensitivity)
- Use more sensitive camera (EMCCD vs CCD)

**Photobleaching:**
- Reduce excitation intensity
- Use anti-fade mounting media
- Image quickly
- Consider more photostable fluorophores
- Use two-photon instead of confocal

---

## Conclusion

Advanced imaging and photodynamic therapy represent powerful tools in the cancer researcher's arsenal. Key principles:

1. **Choose imaging modality based on application**
   - Depth of imaging needed
   - Resolution required
   - Live vs. fixed samples
   - Single vs. longitudinal measurements

2. **PDT is highly dosimetry-dependent**
   - "The extent of the tissue response is modulated by the amounts of both the photosensitizer and the light"¹⁶
   - Careful control and calibration essential
   - Oxygen often the limiting factor

3. **In vivo validation is essential**
   - "Many aspects such as bio-distribution of the photosensitizers, penetration through tissues, and clearance are not taken into account" in vitro¹⁷
   - Orthotopic models most clinically relevant

4. **Quality control is paramount**
   - Calibrate light sources regularly
   - Verify photosensitizer quality
   - Standardize procedures
   - Document all parameters

5. **Multi-modal approaches are most powerful**
   - Combine imaging techniques
   - Validate findings across platforms
   - Use complementary methods

**Future Directions:**
- Improved photosensitizers with better tumor selectivity
- Advanced imaging for real-time PDT monitoring
- Combination therapies (PDT + immunotherapy)
- Personalized dosimetry based on individual tumor characteristics

---

## References

1. Li W. Flow Cytometry in the Diagnosis of Leukemias. In: Leukemia. NCBI Bookshelf; 2022.
2. Kala PS, Zubair M. Flow Cytometry Blood Cell Identification. StatPearls. NCBI Bookshelf; 2024.
3. Cell isolation and culture. WormBook. NCBI Bookshelf; 2006.
4. HSV1-TK/GFP/Fluc. Molecular Imaging and Contrast Agent Database (MICAD). NCBI Bookshelf; 2008.
5. Looking at the Structure of Cells in the Microscope. Molecular Biology of the Cell. 4th edition. NCBI Bookshelf; 2002.
6. Visualizing Molecules in Living Cells. Molecular Biology of the Cell. 4th edition. NCBI Bookshelf; 2002.
7. Biology and Chemistry. Physics of Life. NCBI Bookshelf; 2022.
8. Molecular Biology of the Cell. 4th edition. NCBI Bookshelf; 2002.
9. High-Resolution 3D Light Microscopy with STED and RESOLFT. High Resolution Imaging in Microscopy and Ophthalmology. NCBI Bookshelf; 2019.
10. Molecular imaging of stem cells. StemBook. NCBI Bookshelf; 2009.
11. Methods and Technologies for Studying Metals in Biological Systems. Trace Metals and Infectious Diseases. NCBI Bookshelf; 2014.
12. Ritchie R, et al. In Vivo Bioluminescence Imaging to Assess Compound Efficacy. Trypanosomatids: Methods and Protocols. NCBI Bookshelf; 2020.
13. Photodynamic Therapy for the Eye. StatPearls. NCBI Bookshelf; 2023.
14. Li Y, et al. Photodynamic therapy for oral potentially malignant disorders. PubMed; 2019. PMID: 31394296.
15. Photodynamic Therapy for Dermatologic Conditions. StatPearls. NCBI Bookshelf; 2023.
16. Photodynamic Therapy Dosimetry. Holland-Frei Cancer Medicine. 6th edition. NCBI Bookshelf; 2003.
17. Investigation of the Therapeutic Potential of Nanobody-Targeted Photodynamic Therapy. PubMed; 2022. PMID: 35505029.
18. Olek M, et al. Photodynamic therapy in oral cancer animal models. PubMed; 2021. PMID: 33639322.
19. Nanoparticle-mediated Photodynamic Therapy for Oral Cavity SCC. PubMed; 2024. PMID: 38421899.
20. Matched cohort comparison of mTHPC-PDT and surgery for oral cancer. PubMed; 2014. PMID: 25315968.
21. Nauta JM, et al. Photodynamic therapy of oral cancer. PubMed; 1996. PMID: 8804893.
22. Bimodal lentiviral vector encoding ferritin and GFP. Molecular Imaging and Contrast Agent Database. NCBI Bookshelf; 2011.
23. Photodynamic Therapy for the Eye. StatPearls. NCBI Bookshelf; 2023.
24. MTHPC mediated PDT for head and neck SCC. Database of Abstracts of Reviews of Effects. NCBI Bookshelf; 2013.
25. Fluorescence Lifetime Imaging Ophthalmoscopy. High Resolution Imaging in Microscopy and Ophthalmology. NCBI Bookshelf; 2019.
26. Optical Imaging of Brain Activity Using Genetically Encoded Probes. In Vivo Optical Imaging of Brain Function. NCBI Bookshelf; 2009.

---

**End of Appendix C**

**Additional Resources:**
- Holland-Frei Cancer Medicine - PDT chapter (full protocols)
- Assay Guidance Manual - Flow cytometry methods
- Molecular Imaging and Contrast Agent Database (MICAD)
- PubMed for latest PDT protocols and optimization studies
